Fundraising FoxAisling Capital — 2014 Investments
8 investments dated 2014 · listed companies and verified rows first · show all
Lensar designs and markets laser systems for cataract surgery and corneal astigmatism correction, offering products that incorporate imaging and precision-guidance technologies to help surgeons achieve consistent visual outcomes.
HealthtechOrlando, US
Randy W Frey(Director)Alan B Connaughton(Executive Officer)inAmy R Brooks(Executive Officer)Peter J Mariani(Executive Officer)Keith H Edwards(Executive Officer)Ronald D Goldrich(Executive Officer)
Board seatSteven ElmsJosh Bilenker· per SEC Form D
Co-investorsVersant Venture AIV Holdings
Advion Interchim Scientific provides laboratory instruments, consumables, reagents, and software for chemical analysis and purification tasks such as chromatography, mass spectrometry, and ICP-MS.
BiotechDeep TechEnterprise SoftwareHardwareHealthtechMedical DevicesIthaca, US
John D. Henion(Director)Jamey Jones(Chief Executive Officer)inDavid B. Patteson(Executive Officer, Director)inJoseph M. Kiely(Executive Officer)Wayne Xiong(CFO & Interim CEO/DG)
BoardJohn G. Freund(Director)
Co-investorsGefinor Capital
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.
BiotechHealthtechMedical DevicesDenmark, DK
Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)inGrethe Rasmussen(Executive Officer)inHarald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)Martin Auster(Executive Officer)in
Co-investorsVivo CapitalAvoro Capital AdvisorsForesite CapitalRA CapitalSofinnova PartnersSofinnova Ventures
Biopharma developing HDL-C regulating therapies; listed 2000.
BiotechAnn Arbor, US
Roger S. Newton(Director)inTim M. Mayleben(Executive Officer, Director)
BoardDaniel Janney(Director)Dov A. Goldstein(Director)Nicole Vitullo(Director)inPatrick Enright(Director)in
Co-investorsAlta PartnersArboretum VenturesARCHIMED JapanAsset Management CompanyCanaan PartnersHealthCap+5 more
Global Blood Therapeutics was a South San Francisco biopharmaceutical company founded in 2011 focused on treatments for sickle cell disease.
South San Francisco, US
John Schembri(Executive Officer)inTed W. Love(Executive Officer, Director)in
BoardKevin Starr(Director)inCharles Homcy, M.D.(Director)
Co-investorsAvoro Capital AdvisorsRA CapitalRidgeback CapitalThird Rock VenturesWellington Management
BiotechStamford, US
Joshua H. Bilenker(Executive Officer, Director)
BoardDov Goldstein(Director)James Barrett(Director)David Bonita(Director)Steven Elms(Director)inAvi Naider(Director)
Co-investorsNew Enterprise Associates (NEA)OrbiMed
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
BiotechCambridge, US
Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)
Co-investorsARCH Venture PartnersQuan CapitalAlexandriaAlly Bridge GroupBain CapitalBain Capital Life Sciences+11 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.